Literature DB >> 12426736

[Screening from the epidemiological viewpoint].

N Becker1.   

Abstract

The scope of screening is to identify disease in a clinically inapparent stage in order to treat more effectively. However, the required application of a test to large subsets of the population implies risks which cannot be ignored. Thus, the introduction of a test for use in screening without previously established evidence of a benefit which exceeds potential harm by far cannot be justified. With regard to cancer, evidence of effectiveness has been proven for screening on cervical (Papsmear), breast (mammography) and colorectal (faecal occult blood test) cancer. The routine application of a screening procedure which has been proven effective provides the benefit in terms of mortality reduction seen in the trials only if the entire screening chain, from the test over potentially required assessment to treatment, is offered with highest quality and is under permanent quality control.

Entities:  

Mesh:

Year:  2002        PMID: 12426736     DOI: 10.1007/s00117-002-0777-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  10 in total

1.  Epidemiological aspects of cancer screening in Germany.

Authors:  Nikolaus Becker
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-14       Impact factor: 4.553

Review 2.  [The role of epidemiological quality parameters in a mammography screening programme].

Authors:  N Becker
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

Review 3.  Total-body MR-imaging in oncology.

Authors:  Juergen F Schaefer; Heinz-Peter W Schlemmer
Journal:  Eur Radiol       Date:  2006-04-19       Impact factor: 5.315

Review 4.  [Screening from an epidemiologic perspective].

Authors:  N Becker
Journal:  Radiologe       Date:  2008-01       Impact factor: 0.635

Review 5.  [Epidemiology of lung cancer].

Authors:  N Becker
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

6.  [Epidemiology of prostate cancer].

Authors:  N Becker
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

Review 7.  [Mammography screening].

Authors:  R Schulz-Wendtland; N Becker; K Bock; K Anders; W Bautz
Journal:  Radiologe       Date:  2007-04       Impact factor: 0.635

Review 8.  [Prerequisites for a successful lung cancer screening program].

Authors:  N Becker; S Delorme
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

Review 9.  [Oncologic screening with whole-body MRI: possibilities and limitations].

Authors:  J F Schäfer; A Fischmann; M Lichy; J Vollmar; M Fenchel; C D Claussen; H-P Schlemmer
Journal:  Radiologe       Date:  2004-09       Impact factor: 0.635

10.  Benefit and risk of mammography screening: considerations from an epidemiological viewpoint.

Authors:  Nikolaus Becker; Hans Junkermann
Journal:  Dtsch Arztebl Int       Date:  2008-02-22       Impact factor: 5.594

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.